Float Short %

38.65

Margin Of Safety %

Put/Call OI Ratio

0.46

EPS Next Q Diff

0.19

EPS Last/This Y

0.23

EPS This/Next Y

0.31

Price

5.02

Target Price

6.67

Analyst Recom

2.43

Performance Q

-15.75

Relative Volume

1.9

Beta

0.91

Ticker: RXRX

19 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-06-02	RXRX	4.36	0.38	0.24	342536
2025-06-03	RXRX	4.39	0.38	0.22	346642
2025-06-04	RXRX	4.91	0.38	0.09	349927
2025-06-05	RXRX	4.57	0.35	0.12	379336
2025-06-06	RXRX	5.49	0.36	0.07	385950
2025-06-09	RXRX	5.37	0.34	0.13	399679
2025-06-10	RXRX	5.46	0.35	0.17	409876
2025-06-11	RXRX	5.39	0.36	0.22	427843
2025-06-12	RXRX	5.18	0.37	0.58	435042
2025-06-13	RXRX	4.92	0.39	0.49	458955
2025-06-16	RXRX	5.01	0.42	0.51	441194
2025-06-17	RXRX	4.85	0.42	0.23	452083
2025-06-18	RXRX	5.13	0.42	0.21	453275
2025-06-20	RXRX	5.03	0.42	0.45	455045
2025-06-23	RXRX	4.83	0.47	0.36	364685
2025-06-24	RXRX	5.22	0.47	0.18	371125
2025-06-25	RXRX	5.15	0.46	0.49	378707
2025-06-26	RXRX	5.41	0.47	0.14	383945
2025-06-27	RXRX	5.03	0.46	0.35	386590
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-06-02	RXRX	4.36	11.0	-	-1.46
2025-06-03	RXRX	4.39	11.0	-	-1.46
2025-06-04	RXRX	4.91	11.0	-	-1.46
2025-06-05	RXRX	4.57	11.0	-	-1.46
2025-06-06	RXRX	5.49	11.0	-	-1.46
2025-06-09	RXRX	5.37	11.0	-	-1.46
2025-06-10	RXRX	5.45	11.0	-	-1.46
2025-06-11	RXRX	5.39	11.0	-	-1.46
2025-06-12	RXRX	5.17	14.5	-	-1.46
2025-06-13	RXRX	4.92	14.5	-	-1.44
2025-06-16	RXRX	5.01	14.5	-	-1.44
2025-06-17	RXRX	4.84	14.5	-	-1.44
2025-06-18	RXRX	5.11	14.5	-	-1.44
2025-06-20	RXRX	5.03	12.5	-	-1.46
2025-06-23	RXRX	4.84	12.5	-	-1.46
2025-06-24	RXRX	5.21	12.5	-	-1.46
2025-06-25	RXRX	5.14	12.5	-	-1.46
2025-06-26	RXRX	5.41	12.5	-	-1.46
2025-06-27	RXRX	5.02	12.5	-	-1.46
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-06-02	RXRX	-0.31	-1.34	33.53
2025-06-03	RXRX	-0.31	-1.34	33.53
2025-06-04	RXRX	-0.31	-1.34	33.53
2025-06-05	RXRX	-0.31	-1.34	33.53
2025-06-06	RXRX	-0.31	-1.34	33.53
2025-06-09	RXRX	-0.27	-1.34	33.53
2025-06-10	RXRX	-0.27	-1.34	33.53
2025-06-11	RXRX	-0.27	-1.34	35.08
2025-06-12	RXRX	-0.27	-1.34	35.08
2025-06-13	RXRX	-0.27	-1.34	35.08
2025-06-16	RXRX	-0.27	-1.34	35.08
2025-06-17	RXRX	-0.27	-1.34	35.08
2025-06-18	RXRX	-0.27	-1.34	35.08
2025-06-20	RXRX	-0.27	-1.34	35.08
2025-06-23	RXRX	-0.27	-1.33	35.08
2025-06-24	RXRX	-0.27	-1.33	35.08
2025-06-25	RXRX	-0.27	-1.33	35.08
2025-06-26	RXRX	-0.27	-1.33	38.64
2025-06-27	RXRX	-0.27	-1.33	38.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.5

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.31

Insider Transactions

-0.27

Institutional Transactions

-1.33

Beta

0.91

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

88.3

Max Drawdown 5-Year %

Target Price

6.67

P/E

Forward P/E

PEG

P/S

34.2

P/B

2.19

P/Free Cash Flow

EPS

-1.78

Average EPS Est. Cur. Y

-1.46

EPS Next Y. (Est.)

-1.14

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-961.32

Relative Volume

1.9

Return on Equity vs Sector %

-85.4

Return on Equity vs Industry %

-67.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Recursion Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 800

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

stock quote shares RXRX – Recursion Pharmaceuticals, Inc. Stock Price stock today

news today RXRX – Recursion Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RXRX – Recursion Pharmaceuticals, Inc. yahoo finance google finance

stock history RXRX – Recursion Pharmaceuticals, Inc. invest stock market

stock prices RXRX premarket after hours

ticker RXRX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RXRX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y